{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:00:20Z","timestamp":1793052020772,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI108197"],"award-info":[{"award-number":["AI108197"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI132178"],"award-info":[{"award-number":["AI132178"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI157155"],"award-info":[{"award-number":["AI157155"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41591-021-01282-0","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T17:02:40Z","timestamp":1615827760000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":249,"title":["Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2799-3754","authenticated-orcid":false,"given":"Rita M.","family":"Meganck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"1282_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"1282_CR2","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1073\/pnas.1517719113","volume":"113","author":"VD Menachery","year":"2016","unstructured":"Menachery, V. D. et al. SARS-like WIV1-CoV poised for human emergence. Proc. Natl Acad. Sci. USA 113, 3048\u20133053 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1282_CR3","doi-asserted-by":"publisher","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1282_CR4","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1282_CR5","doi-asserted-by":"publisher","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2021436 (2020).","DOI":"10.1056\/nejmoa2021436"},{"key":"1282_CR6","doi-asserted-by":"publisher","unstructured":"Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2029849 (2020).","DOI":"10.1056\/nejmoa2029849"},{"key":"1282_CR7","doi-asserted-by":"publisher","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2035002 (2020).","DOI":"10.1056\/nejmoa2035002"},{"key":"1282_CR8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR9","doi-asserted-by":"publisher","unstructured":"Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2031994 (2020).","DOI":"10.1056\/nejmoa2031994"},{"key":"1282_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"1282_CR11","doi-asserted-by":"publisher","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2035389 (2020).","DOI":"10.1056\/nejmoa2035389"},{"key":"1282_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396, 1979\u20131993 (2020).","journal-title":"Lancet"},{"key":"1282_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.abf4830","volume":"371","author":"CG Rappazzo","year":"2021","unstructured":"Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823\u2013829 (2021).","journal-title":"Science"},{"key":"1282_CR15","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508\u20131513 (2015).","journal-title":"Nat. Med."},{"key":"1282_CR16","doi-asserted-by":"publisher","first-page":"26915","DOI":"10.1073\/pnas.2001046117","volume":"117","author":"CE Edwards","year":"2020","unstructured":"Edwards, C. E. et al. Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. Proc. Natl Acad. Sci. USA 117, 26915\u201326925 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1282_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.prrv.2004.07.009","volume":"5","author":"JD Cherry","year":"2004","unstructured":"Cherry, J. D. The chronology of the 2002\u20132003 SARS mini pandemic. Paediatr. Respir. Rev. 5, 262\u2013269 (2004).","journal-title":"Paediatr. Respir. Rev."},{"key":"1282_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1371\/journal.ppat.1004457","volume":"10","author":"A Sharif-Yakan","year":"2014","unstructured":"Sharif-Yakan, A. & Kanj, S. S. Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives. PLoS Pathog. 10, 10\u201313 (2014).","journal-title":"PLoS Pathog."},{"key":"1282_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"W Li","year":"2005","unstructured":"Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676\u2013680 (2005).","journal-title":"Science"},{"key":"1282_CR20","doi-asserted-by":"publisher","first-page":"e00116-18","DOI":"10.1128\/JVI.00116-18","volume":"92","author":"C-M Luo","year":"2018","unstructured":"Luo, C.-M. et al. Discovery of novel bat coronaviruses in South China that use the same receptor as Middle East respiratory syndrome coronavirus. J. Virol. 92, e00116-18 (2018).","journal-title":"J. Virol."},{"key":"1282_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S0966-842X(01)02288-0","volume":"10","author":"DJ Gulber","year":"2002","unstructured":"Gulber, D. J. Epidemic dengue\/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10, 100\u2013103 (2002).","journal-title":"Trends Microbiol."},{"key":"1282_CR22","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","volume":"15","author":"SJ Thomas","year":"2019","unstructured":"Thomas, S. J. & Yoon, I. K. A review of Dengvaxia\u00ae: development to deployment. Hum. Vaccines Immunother. 15, 2295\u20132314 (2019).","journal-title":"Hum. Vaccines Immunother."},{"key":"1282_CR23","doi-asserted-by":"publisher","first-page":"S976","DOI":"10.1093\/infdis\/jix405","volume":"216","author":"EB Kauffman","year":"2017","unstructured":"Kauffman, E. B. & Kramer, L. D. Zika virus mosquito vectors: competence, biology, and vector control. J. Infect. Dis. 216, S976\u2013S990 (2017).","journal-title":"J. Infect. Dis."},{"key":"1282_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/oxfordjournals.epirev.a017917","volume":"18","author":"WP Glezen","year":"1996","unstructured":"Glezen, W. P. Emerging infections: pandemic influenza. Epidemiol. Rev. 18, 64\u201376 (1996).","journal-title":"Epidemiol. Rev."},{"key":"1282_CR25","first-page":"e00137","volume":"6","author":"MT Osterholm","year":"2015","unstructured":"Osterholm, M. T. et al. Transmission of Ebola viruses: what we know and what we do not know. mBio 6, e00137 (2015).","journal-title":"mBio"},{"key":"1282_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nature08157","volume":"459","author":"G Neumann","year":"2009","unstructured":"Neumann, G., Noda, T. & Kawaoka, Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459, 931\u2013939 (2009).","journal-title":"Nature"},{"key":"1282_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/cr.2009.124","volume":"20","author":"G Neumann","year":"2010","unstructured":"Neumann, G., Chen, H., Gao, G. F., Shu, Y. & Kawaoka, Y. H5N1 influenza viruses: outbreaks and biological properties. Cell Res. 20, 51\u201361 (2010).","journal-title":"Cell Res."},{"key":"1282_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"1282_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nature19790","volume":"538","author":"EC Holmes","year":"2016","unstructured":"Holmes, E. C., Dudas, G., Rambaut, A. & Andersen, K. G. The evolution of Ebola virus: insights from the 2013\u20132016 epidemic. Nature 538, 193\u2013200 (2016).","journal-title":"Nature"},{"key":"1282_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1056\/NEJMsr1904253","volume":"381","author":"O Ilunga Kalenga","year":"2019","unstructured":"Ilunga Kalenga, O. et al. The ongoing Ebola epidemic in the Democratic Republic of Congo, 2018\u20132019. N. Engl. J. Med. 381, 373\u2013383 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"1282_CR32","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1099\/vir.0.82714-0","volume":"88","author":"VA Arankalle","year":"2007","unstructured":"Arankalle, V. A. et al. Genetic divergence of Chikungunya viruses in India (1963\u20132006) with special reference to the 2005\u20132006 explosive epidemic. J. Gen. Virol. 88, 1967\u20131976 (2007).","journal-title":"J. Gen. Virol."},{"key":"1282_CR33","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","volume":"17","author":"FJ Burt","year":"2017","unstructured":"Burt, F. J. et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect. Dis. 17, e107\u2013e117 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"1282_CR34","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.4269\/ajtmh.17-0927","volume":"98","author":"NP Lindsey","year":"2018","unstructured":"Lindsey, N. P., Staples, J. E. & Fischer, M. Eastern equine encephalitis virus in the United States, 2003\u20132016. Am. J. Trop. Med. Hyg. 98, 1472\u20131477 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1282_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0005693","volume":"11","author":"NL Forrester","year":"2017","unstructured":"Forrester, N. L. et al. Evolution and spread of Venezuelan equine encephalitis complex alphavirus in the Americas. PLoS Negl. Trop. Dis. 11, 1\u201319 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1282_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","volume":"100","author":"DA Bente","year":"2013","unstructured":"Bente, D. A. et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir. Res. 100, 159\u2013189 (2013).","journal-title":"Antivir. Res."},{"key":"1282_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1128\/CMR.00062-09","volume":"23","author":"CB Jonsson","year":"2010","unstructured":"Jonsson, C. B., Figueiredo, L. T. M. & Vapalahti, O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 23, 412\u2013441 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"1282_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coviro.2019.07.009","volume":"37","author":"LE Garnett","year":"2019","unstructured":"Garnett, L. E. & Strong, J. E. Lassa fever: with 50 years of study, hundreds of thousands of patients and an extremely high disease burden, what have we learned? Curr. Opin. Virol. 37, 123\u2013131 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"1282_CR39","doi-asserted-by":"publisher","unstructured":"Himeidan, Y. E., Kweka, E. J., Mahgoub, M. M., El Rayah, E. A. & Ouma, J. O. Recent outbreaks of Rift Valley fever in East Africa and the Middle East. Front. Public Health https:\/\/doi.org\/10.3389\/fpubh.2014.00169 (2014).","DOI":"10.3389\/fpubh.2014.00169"},{"key":"1282_CR40","doi-asserted-by":"publisher","unstructured":"Pillai, V. S., Krishna, G. & Veettil, M. V. Nipah virus: past outbreaks and future containment. Viruses 12, https:\/\/doi.org\/10.3390\/v12040465 (2020).","DOI":"10.3390\/v12040465"},{"key":"1282_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.coviro.2016.02.004","volume":"16","author":"HE Field","year":"2016","unstructured":"Field, H. E. Hendra virus ecology and transmission. Curr. Opin. Virol. 16, 120\u2013125 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"1282_CR42","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3201\/eid2003.131159","volume":"20","author":"D Middleton","year":"2014","unstructured":"Middleton, D. et al. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg. Infect. Dis. 20, 372\u2013379 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"1282_CR43","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1099\/jgv.0.001318","volume":"100","author":"P Chhabra","year":"2019","unstructured":"Chhabra, P. et al. Updated classification of norovirus genogroups and genotypes. J. Gen. Virol. 100, 1393\u20131406 (2019).","journal-title":"J. Gen. Virol."},{"key":"1282_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrmicro.2016.48","volume":"14","author":"M De Graaf","year":"2016","unstructured":"De Graaf, M., Van Beek, J. & Koopmans, M. P. G. Human norovirus transmission and evolution in a changing world. Nat. Rev. Microbiol. 14, 421\u2013433 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"1282_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.20506\/rst.36.2.2669","volume":"36","author":"JH Epstein","year":"2017","unstructured":"Epstein, J. H. & Anthony, S. J. Viral discovery as a fool for pandemic preparedness. Rev. Sci. Tech. 36, 499\u2013512 (2017).","journal-title":"Rev. Sci. Tech."},{"key":"1282_CR46","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR47","doi-asserted-by":"publisher","first-page":"e1486","DOI":"10.1371\/journal.pntd.0001486","volume":"6","author":"WB Messer","year":"2012","unstructured":"Messer, W. B. et al. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl. Trop. Dis. 6, e1486 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1282_CR48","doi-asserted-by":"publisher","first-page":"12995","DOI":"10.1073\/pnas.1735582100","volume":"100","author":"B Yount","year":"2003","unstructured":"Yount, B. et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 100, 12995\u201313000 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1282_CR49","first-page":"eabe8499","volume":"1468","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 1468, eabe8499 (2020).","journal-title":"Science"},{"key":"1282_CR50","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s12275-012-2163-9","volume":"50","author":"J Kim II","year":"2012","unstructured":"Kim, J. II et al. GFP-expressing influenza a virus for evaluation of the efficacy of antiviral agents. J. Microbiol. 50, 359\u2013362 (2012).","journal-title":"J. Microbiol."},{"key":"1282_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.antiviral.2011.05.001","volume":"91","author":"G Zou","year":"2011","unstructured":"Zou, G., Xu, H. Y., Qing, M., Wang, Q. Y. & Shi, P. Y. Development and characterization of a stable luciferase dengue virus for high-throughput screening. Antivir. Res. 91, 11\u201319 (2011).","journal-title":"Antivir. Res."},{"key":"1282_CR52","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1128\/JVI.03368-12","volume":"87","author":"R Dijkman","year":"2013","unstructured":"Dijkman, R. et al. Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism. J. Virol. 87, 6081\u20136090 (2013).","journal-title":"J. Virol."},{"key":"1282_CR53","doi-asserted-by":"publisher","unstructured":"Tang, H., Abouleila, Y. & Mashaghi, A. Lassa hemorrhagic shock syndrome-on-a-chip. Biotechnol. Bioeng. https:\/\/doi.org\/10.1002\/bit.27636 (2020).","DOI":"10.1002\/bit.27636"},{"key":"1282_CR54","doi-asserted-by":"publisher","unstructured":"Zhang, M. et al. Biomimetic human disease model of SARS-CoV-2-induced lung injury and immune responses on organ chip system. Adv. Sci. https:\/\/doi.org\/10.1002\/advs.202002928 (2020).","DOI":"10.1002\/advs.202002928"},{"key":"1282_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.stem.2020.06.015","volume":"27","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 27, 125\u2013136 (2020).","journal-title":"Cell Stem Cell"},{"key":"1282_CR56","doi-asserted-by":"crossref","unstructured":"The Complex Trait Consortium. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat. Genet. 36, 1133\u20131137 (2018)..","DOI":"10.1038\/ng1104-1133"},{"key":"1282_CR57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743 (2020).","journal-title":"Cell"},{"key":"1282_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124\u2013133 (2020).","journal-title":"Cell Host Microbe"},{"key":"1282_CR59","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li, W. et al. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Nature 426, 450\u2013454 (2003).","journal-title":"Nature"},{"key":"1282_CR60","doi-asserted-by":"publisher","first-page":"e01933-17","DOI":"10.1128\/JVI.01933-17","volume":"92","author":"A Milewska","year":"2018","unstructured":"Milewska, A. et al. Entry of human coronavirus NL63 into the cell. J. Virol. 92, e01933-17 (2018).","journal-title":"J. Virol."},{"key":"1282_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.virol.2017.12.015","volume":"517","author":"JK Millet","year":"2018","unstructured":"Millet, J. K. & Whittaker, G. R. Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology 517, 3\u20138 (2018).","journal-title":"Virology"},{"key":"1282_CR62","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun. 10, 2342 (2019).","journal-title":"Nat. Commun."},{"key":"1282_CR63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/312242a0","volume":"312","author":"J De Villiers","year":"1984","unstructured":"De Villiers, J., Schaffner, W., Tyndall, C., Lupton, S. & Kamen, R. Polyoma virus DNA replication requires an enhancer. Nature 312, 242\u2013246 (1984).","journal-title":"Nature"},{"key":"1282_CR64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev-virology-100114-055014","volume":"3","author":"E Jan","year":"2016","unstructured":"Jan, E., Mohr, I. & Walsh, D. A cap-to-tail guide to mRNA translation strategies in virus-infected cells. Annu. Rev. Virol. 3, 283\u2013307 (2016).","journal-title":"Annu. Rev. Virol."},{"key":"1282_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","volume":"174","author":"BW Neuman","year":"2011","unstructured":"Neuman, B. W. et al. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol. 174, 11\u201322 (2011).","journal-title":"J. Struct. Biol."},{"key":"1282_CR66","doi-asserted-by":"publisher","first-page":"28046","DOI":"10.1073\/pnas.2016093117","volume":"117","author":"A Glasgow","year":"2020","unstructured":"Glasgow, A. et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 28046\u201328055 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1282_CR67","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.abe0075","volume":"370","author":"TW Linsky","year":"2020","unstructured":"Linsky, T. W. et al. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science 370, 1208\u20131214 (2020).","journal-title":"Science"},{"key":"1282_CR68","doi-asserted-by":"publisher","first-page":"e106275","DOI":"10.15252\/embj.2020106275","volume":"39","author":"T Klemm","year":"2020","unstructured":"Klemm, T. et al. Mechanism and inhibition of the papain\u2010like protease, PLpro, of SARS\u2010CoV\u20102. EMBO J. 39, e106275 (2020).","journal-title":"EMBO J."},{"key":"1282_CR69","doi-asserted-by":"publisher","unstructured":"Chen, C.-C. et al. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. FEBS J. https:\/\/doi.org\/10.1111\/febs.15696 (2021).","DOI":"10.1111\/febs.15696"},{"key":"1282_CR70","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1128\/AAC.40.9.2004","volume":"40","author":"KP Anderson","year":"1996","unstructured":"Anderson, K. P., Fox, M. C., Brown-Driver, V., Martin, M. J. & Azad, R. F. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40, 2004\u20132011 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1282_CR71","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","volume":"495","author":"VS Raj","year":"2013","unstructured":"Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251\u2013254 (2013).","journal-title":"Nature"},{"key":"1282_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-59745-178-9_2","volume":"440","author":"AI Ivanov","year":"2008","unstructured":"Ivanov, A. I. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol. Biol. 440, 15\u201333 (2008).","journal-title":"Methods Mol. Biol."},{"key":"1282_CR73","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1128\/JVI.00253-07","volume":"81","author":"Y Inoue","year":"2007","unstructured":"Inoue, Y. et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J. Virol. 81, 8722\u20138729 (2007).","journal-title":"J. Virol."},{"key":"1282_CR74","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Y Zhou","year":"2015","unstructured":"Zhou, Y. et al. Protease inhibitors targeting coronavirus and filovirus entry. Antivir. Res. 116, 76\u201384 (2015).","journal-title":"Antivir. Res."},{"key":"1282_CR75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41467-018-08015-x","volume":"10","author":"S Yuan","year":"2019","unstructured":"Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat. Commun. 10, 120 (2019).","journal-title":"Nat. Commun."},{"key":"1282_CR76","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.jpclett.0c00571","volume":"11","author":"WF Zhang","year":"2020","unstructured":"Zhang, W. F. et al. Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. J. Phys. Chem. Lett. 11, 4430\u20134435 (2020).","journal-title":"J. Phys. Chem. Lett."},{"key":"1282_CR77","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763\u20131767 (2003).","journal-title":"Science"},{"key":"1282_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cti2.1073","volume":"8","author":"E Braun","year":"2019","unstructured":"Braun, E. & Sauter, D. Furin-mediated protein processing in infectious diseases and cancer. Clin. Transl. Immunol. 8, 1\u201319 (2019).","journal-title":"Clin. Transl. Immunol."},{"key":"1282_CR79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cell.2020.10.028","volume":"184","author":"J Wei","year":"2021","unstructured":"Wei, J. et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell 184, 76\u201391 (2021).","journal-title":"Cell"},{"key":"1282_CR80","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/jcm9020538","volume":"9","author":"N Linton","year":"2020","unstructured":"Linton, N. et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. J. Clin. Med. 9, 538 (2020).","journal-title":"J. Clin. Med."},{"key":"1282_CR81","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","volume":"361","author":"JSM Peiris","year":"2003","unstructured":"Peiris, J. S. M. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767\u20131772 (2003).","journal-title":"Lancet"},{"key":"1282_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.onehlt.2016.12.001","volume":"3","author":"W Widagdo","year":"2017","unstructured":"Widagdo, W., Okba, N. M. A., Stalin Raj, V. & Haagmans, B. L. MERS-coronavirus: from discovery to intervention. One Health 3, 11\u201316 (2017).","journal-title":"One Health"},{"key":"1282_CR83","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jiph.2019.04.002","volume":"12","author":"AE Ahmed","year":"2019","unstructured":"Ahmed, A. E. Diagnostic delays in Middle East respiratory syndrome coronavirus patients and health systems. J. Infect. Public Health 12, 767\u2013771 (2019).","journal-title":"J. Infect. Public Health"},{"key":"1282_CR84","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cmi.2020.06.020","volume":"26","author":"JW Yang","year":"2020","unstructured":"Yang, J. W., Yang, L., Luo, R. G. & Xu, J. F. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin. Microbiol. Infect. 26, 1171\u20131177 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"1282_CR85","doi-asserted-by":"publisher","first-page":"e12697","DOI":"10.15252\/emmm.202012697","volume":"12","author":"J Stebbing","year":"2020","unstructured":"Stebbing, J. et al. Mechanism of baricitinib supports artificial intelligence\u2010predicted testing in COVID\u201019 patients. EMBO Mol. Med. 12, e12697 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1282_CR86","doi-asserted-by":"publisher","first-page":"10","DOI":"10.15252\/emmm.202012465","volume":"12","author":"E Andreakos","year":"2020","unstructured":"Andreakos, E. & Tsiodras, S. COVID\u201019: lambda interferon against viral load and hyperinflammation. EMBO Mol. Med. 12, 10\u201313 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1282_CR87","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EWM Ng","year":"2006","unstructured":"Ng, E. W. M. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123\u2013132 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1282_CR88","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819\u2013829 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR89","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22\u201331 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR90","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani, M. et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N. Engl. J. Med. 382, 2289\u20132301 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR91","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634\u20131644 (2010).","journal-title":"Genes Dev."},{"key":"1282_CR92","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.1178178","volume":"327","author":"RE Lanford","year":"2010","unstructured":"Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198\u2013201 (2010).","journal-title":"Science"},{"key":"1282_CR93","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1525-0016(03)00244-2","volume":"8","author":"H Giladi","year":"2003","unstructured":"Giladi, H. et al. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. 8, 769\u2013776 (2003).","journal-title":"Mol. Ther."},{"key":"1282_CR94","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","volume":"26","author":"D Sarker","year":"2020","unstructured":"Sarker, D. et al. MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-\u03b1, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial. Clin. Cancer Res. 26, 3936\u20133946 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1282_CR95","doi-asserted-by":"publisher","first-page":"eaaw6647","DOI":"10.1126\/sciimmunol.aaw6647","volume":"4","author":"N Kose","year":"2019","unstructured":"Kose, N. et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 4, eaaw6647 (2019).","journal-title":"Sci. Immunol."},{"key":"1282_CR96","doi-asserted-by":"publisher","first-page":"10450","DOI":"10.1021\/bi00200a028","volume":"33","author":"D Jellinek","year":"1994","unstructured":"Jellinek, D., Green, L. S., Bell, C. & Janji\u0107, N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33, 10450\u201310456 (1994).","journal-title":"Biochemistry"},{"key":"1282_CR97","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","volume":"181","author":"TR Abbott","year":"2020","unstructured":"Abbott, T. R. et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell 181, 865\u2013876 (2020).","journal-title":"Cell"},{"key":"1282_CR98","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash, T. P. et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796\u20138807 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1282_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","volume":"237","author":"T Sugo","year":"2016","unstructured":"Sugo, T. et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J. Control. Release 237, 1\u201313 (2016).","journal-title":"J. Control. Release"},{"key":"1282_CR100","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/thno.23085","volume":"8","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8, 1575\u20131590 (2018).","journal-title":"Theranostics"},{"key":"1282_CR101","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","volume":"9","author":"N Veiga","year":"2018","unstructured":"Veiga, N. et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat. Commun. 9, 4493 (2018).","journal-title":"Nat. Commun."},{"key":"1282_CR102","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","volume":"9","author":"L Carlsson","year":"2018","unstructured":"Carlsson, L. et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine. Mol. Ther. Methods Clin. Dev. 9, 330\u2013346 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1282_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2011.04.009","volume":"91","author":"DG Ahn","year":"2011","unstructured":"Ahn, D. G. et al. Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication. Antivir. Res. 91, 1\u201310 (2011).","journal-title":"Antivir. Res."},{"key":"1282_CR104","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/pathogens9110925","volume":"9","author":"M Szabat","year":"2020","unstructured":"Szabat, M. et al. RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication. Pathogens 9, 925 (2020).","journal-title":"Pathogens"},{"key":"1282_CR105","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3390\/cells8121555","volume":"8","author":"C Whitten-Bauer","year":"2019","unstructured":"Whitten-Bauer, C. et al. The host factor Erlin-1 is required for efficient hepatitis C virus infection. Cells 8, 1555 (2019).","journal-title":"Cells"},{"key":"1282_CR106","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1385\/MB:33:2:141","volume":"33","author":"B Meng","year":"2006","unstructured":"Meng, B., Lui, Y. W., Meng, S., Cao, C. & Hu, Y. Identification of effective siRNA blocking the expression of SARS viral envelope E and RDRP genes. Mol. Biotechnol. 33, 141\u2013148 (2006).","journal-title":"Mol. Biotechnol."},{"key":"1282_CR107","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nature24034","volume":"550","author":"C Gorbea","year":"2017","unstructured":"Gorbea, C., Mosbruger, T. & Cazalla, D. A viral Sm-class RNA base-pairs with mRNAs and recruits microRNAs to inhibit apoptosis. Nature 550, 275\u2013279 (2017).","journal-title":"Nature"},{"key":"1282_CR108","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/vbz.2014.1759","volume":"15","author":"EJ Flies","year":"2015","unstructured":"Flies, E. J., Toi, C., Weinstein, P., Doggett, S. L. & Williams, C. R. Converting mosquito surveillance to arbovirus surveillance with honey-baited nucleic acid preservation cards. Vector-Borne Zoonotic Dis. 15, 397\u2013403 (2015).","journal-title":"Vector-Borne Zoonotic Dis."},{"key":"1282_CR109","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/v11030240","volume":"11","author":"KL Phelps","year":"2019","unstructured":"Phelps, K. L. et al. Bat research networks and viral surveillance: gaps and opportunities in western Asia. Viruses 11, 240 (2019).","journal-title":"Viruses"},{"key":"1282_CR110","doi-asserted-by":"publisher","unstructured":"Yang, L. et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol. Sin. https:\/\/doi.org\/10.1038\/s41401-020-00556-6 (2020).","DOI":"10.1038\/s41401-020-00556-6"},{"key":"1282_CR111","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113\u2013119 (2020).","journal-title":"Nature"},{"key":"1282_CR112","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"AH De Wilde","year":"2014","unstructured":"De Wilde, A. H. et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875\u20134884 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1282_CR113","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3201\/eid1004.030458","volume":"10","author":"ELC Tan","year":"2004","unstructured":"Tan, E. L. C. et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10, 581\u2013586 (2004).","journal-title":"Emerg. Infect. Dis."},{"key":"1282_CR114","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR115","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/cr.2015.113","volume":"25","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25, 1237\u20131249 (2015).","journal-title":"Cell Res."},{"key":"1282_CR116","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding, F. A., Stickler, M. M., Razo, J. & DuBridge, R. B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2, 256\u2013265 (2010).","journal-title":"MAbs"},{"key":"1282_CR117","doi-asserted-by":"publisher","first-page":"8738","DOI":"10.1073\/pnas.1510830112","volume":"112","author":"KE Pascal","year":"2015","unstructured":"Pascal, K. E. et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 112, 8738\u20138743 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1282_CR118","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"1282_CR119","doi-asserted-by":"publisher","first-page":"598038","DOI":"10.3389\/fmed.2020.598038","volume":"7","author":"H Hashem","year":"2020","unstructured":"Hashem, H., Abufaraj, M., Tbakhi, A., & Sultan, I. Obstacles and considerations related to clinical trial research during the COVID-19 pandemic. Front. Med. 7, 598038 (2020).","journal-title":"Front. Med."},{"key":"1282_CR120","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IFN Hung","year":"2020","unstructured":"Hung, I. F. N. et al. Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695\u20131704 (2020).","journal-title":"Lancet"},{"key":"1282_CR121","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","volume":"14","author":"J Haffizulla","year":"2014","unstructured":"Haffizulla, J. et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial. Lancet Infect. Dis. 14, 609\u2013618 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"1282_CR122","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(06)68852-1","volume":"368","author":"JF Rossignol","year":"2006","unstructured":"Rossignol, J. F., Abu-Zekry, M., Hussein, A. & Santoro, M. G. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368, 124\u2013129 (2006).","journal-title":"Lancet"},{"key":"1282_CR123","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai, Q. et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 6, 1192\u20131198 (2020).","journal-title":"Engineering"},{"key":"1282_CR124","doi-asserted-by":"publisher","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","volume":"13","author":"D Sissoko","year":"2016","unstructured":"Sissoko, D. et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 13, e1001967 (2016).","journal-title":"PLoS Med."},{"key":"1282_CR125","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","volume":"87","author":"KA Eberhardt","year":"2019","unstructured":"Eberhardt, K. A. et al. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int. J. Infect. Dis. 87, 15\u201320 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"1282_CR126","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/ana.1062","volume":"49","author":"HT Chong","year":"2001","unstructured":"Chong, H. T. et al. Treatment of acute Nipah encephalitis with ribavirin. Ann. Neurol. 49, 810\u2013813 (2001).","journal-title":"Ann. Neurol."},{"key":"1282_CR127","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","volume":"151","author":"IFN Hung","year":"2017","unstructured":"Hung, I. F. N. et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb\/III trial. Chest 151, 1069\u20131080 (2017).","journal-title":"Chest"},{"key":"1282_CR128","doi-asserted-by":"publisher","first-page":"e0147917","DOI":"10.1371\/journal.pone.0147917","volume":"11","author":"L Hampson","year":"2016","unstructured":"Hampson, L. et al. A single-arm, proof-of-concept trial of Lopimune (lopinavir\/ritonavir) as a treatment for HPV-related pre-invasive cervical disease. PLoS ONE 11, e0147917 (2016).","journal-title":"PLoS ONE"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01282-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:34:23Z","timestamp":1733960063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01282-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01282-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.B. has competing interests regarding collaborative research with Gilead Sciences, Ridgeback Biotherapeutics, Takeda, Pfizer, Eli Lily, Adimab and Moderna Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}